Cargando…
Repeated dose of prostaglandin E2 vaginal insert when the first dose fails
OBJECTIVE: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails. MATERIALS AND METHODS: This retrospective study included 1.043 pregnant women who received dinoprostone for labor induction betwe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962160/ https://www.ncbi.nlm.nih.gov/pubmed/33715333 http://dx.doi.org/10.4274/tjod.galenos.2021.34119 |
_version_ | 1783665414832652288 |
---|---|
author | Karadağ, Ceyda Esin, Sertaç Tohma, Yusuf Aytaç Yalvaç, Ethem Serdar Başar, Tuğrul Karadağ, Burak |
author_facet | Karadağ, Ceyda Esin, Sertaç Tohma, Yusuf Aytaç Yalvaç, Ethem Serdar Başar, Tuğrul Karadağ, Burak |
author_sort | Karadağ, Ceyda |
collection | PubMed |
description | OBJECTIVE: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails. MATERIALS AND METHODS: This retrospective study included 1.043 pregnant women who received dinoprostone for labor induction between November 2012 and August 2015. Pregnant women were divided into two groups according to the number of dinoprostone administrations: group 1, single-dose dinoprostone (n=1.000), and group 2, repeated-dose dinoprostone (n=43). Intrapartum, postpartum, and neonatal outcomes of the pregnant women were compared. RESULTS: Vaginal delivery rate was 65% in group 1 and 30.2% in group 2 (p=0.001). The need for the neonatal intensive care unit was found in 44 pregnant women (4.4%) in group 1 and 6 pregnant women (13.6%) in group 2 (p=0.006). CONCLUSION: When obstetric and neonatal data were evaluated in our study, we observed that dinoprostone administration was associated with increased cesarean rates and adverse neonatal outcomes with repeated-dose dinoprostone when the first dose failed. |
format | Online Article Text |
id | pubmed-7962160 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-79621602021-03-25 Repeated dose of prostaglandin E2 vaginal insert when the first dose fails Karadağ, Ceyda Esin, Sertaç Tohma, Yusuf Aytaç Yalvaç, Ethem Serdar Başar, Tuğrul Karadağ, Burak Turk J Obstet Gynecol Clinical Investigation OBJECTIVE: To compare the obstetric and neonatal outcomes of patients treated with repeated-dose prostaglandin E2 (dinoprostone) vaginal insert when the first dose fails. MATERIALS AND METHODS: This retrospective study included 1.043 pregnant women who received dinoprostone for labor induction between November 2012 and August 2015. Pregnant women were divided into two groups according to the number of dinoprostone administrations: group 1, single-dose dinoprostone (n=1.000), and group 2, repeated-dose dinoprostone (n=43). Intrapartum, postpartum, and neonatal outcomes of the pregnant women were compared. RESULTS: Vaginal delivery rate was 65% in group 1 and 30.2% in group 2 (p=0.001). The need for the neonatal intensive care unit was found in 44 pregnant women (4.4%) in group 1 and 6 pregnant women (13.6%) in group 2 (p=0.006). CONCLUSION: When obstetric and neonatal data were evaluated in our study, we observed that dinoprostone administration was associated with increased cesarean rates and adverse neonatal outcomes with repeated-dose dinoprostone when the first dose failed. Galenos Publishing 2021-03 2021-03-12 /pmc/articles/PMC7962160/ /pubmed/33715333 http://dx.doi.org/10.4274/tjod.galenos.2021.34119 Text en ©Copyright 2021 by Turkish Society of Obstetrics and Gynecology | Turkish Journal of Obstetrics and Gynecology published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Investigation Karadağ, Ceyda Esin, Sertaç Tohma, Yusuf Aytaç Yalvaç, Ethem Serdar Başar, Tuğrul Karadağ, Burak Repeated dose of prostaglandin E2 vaginal insert when the first dose fails |
title | Repeated dose of prostaglandin E2 vaginal insert when the first dose fails |
title_full | Repeated dose of prostaglandin E2 vaginal insert when the first dose fails |
title_fullStr | Repeated dose of prostaglandin E2 vaginal insert when the first dose fails |
title_full_unstemmed | Repeated dose of prostaglandin E2 vaginal insert when the first dose fails |
title_short | Repeated dose of prostaglandin E2 vaginal insert when the first dose fails |
title_sort | repeated dose of prostaglandin e2 vaginal insert when the first dose fails |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962160/ https://www.ncbi.nlm.nih.gov/pubmed/33715333 http://dx.doi.org/10.4274/tjod.galenos.2021.34119 |
work_keys_str_mv | AT karadagceyda repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails AT esinsertac repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails AT tohmayusufaytac repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails AT yalvacethemserdar repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails AT basartugrul repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails AT karadagburak repeateddoseofprostaglandine2vaginalinsertwhenthefirstdosefails |